F74. CLINICAL SYMPTOMS AND NOT OBJECTIVE COGNITIVE PERFORMANCE DRIVE SUBJECTIVE COGNITIVE COMPLAINTS IN PATIENTS WITH SCHIZOPHRENIA

BACKGROUND: The United States Food and Drug Administration (FDA) recommends that drugs that exert a pro-cognitive effect should be accompanied by measurable improvements in ‘real-world’ functioning. Patients with schizophrenia typically exhibit substantial impairments across a wide range of cognitiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Cotter, Jack, Granger, Kiri, Evenden, John, Barnett, Jennifer, Sand, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888865/
http://dx.doi.org/10.1093/schbul/sby017.605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888865/
http://dx.doi.org/10.1093/schbul/sby017.605

Ejemplares similares